Key result
Tirofiban matches abciximab for platelet inhibition during PCI while lowering the risk of thrombocytopenia.
Why the study?
Platelet aggregation plays a vital role in atherothrombosis and PCI complications, motivating a comparison of the efficacy and safety of tirofiban versus abciximab.
Does tirofiban improve platelet aggregation and clinical outcomes compared to abciximab in patients undergoing percutaneous coronary interventions?
Systematic Review (n=539)
Does tirofiban improve platelet aggregation and clinical outcomes compared to abciximab in patients undergoing percutaneous coronary interventions?
In patients undergoing PCI, tirofiban provides comparable platelet inhibition to abciximab but with a lower risk of thrombocytopenia and greater dosing flexibility.
Clinicians may favor tirofiban over abciximab in PCI to reduce thrombocytopenia; extends RCT evidence via systematic synthesis.
Platelet aggregation plays a vital role in atherothrombosis and percutaneous coronary intervention (PCI) complications. In this systematic review, tirofiban and abciximab, glycoprotein IIb/IIIa inhibitors, were compared for efficacy and safety in PCI, based on five randomized trials and 539 participants, adhering to the Preferred Reporting Items for Systematic Reviews and Meta-analyses guidelines. Both drugs were effective and tolerable in most cases. Tirofiban had a reduced risk of thrombocytopenia and comparable rates of bleeding to abciximab. Intracoronary tirofiban has potential over intravenous administration, particularly in ST-elevation myocardial infarction, with better 30-day outcomes and thrombolysis in myocardial infarction grade 3 flow, without an increased risk of bleeding. The choice of treatment should be based on the individual patient. Future clinical benefits should be substantiated by larger trials to provide guidance for best practices.
No takes yet. Share an insight, caveat, or question.
Mathur et al. (2026) conducted a systematic review in Percutaneous coronary intervention (n=539). Tirofiban vs. Abciximab was evaluated on Platelet aggregation and inhibition. Tirofiban and abciximab demonstrated comparable efficacy in inhibiting platelet aggregation during percutaneous coronary intervention, with tirofiban showing a reduced risk of thrombocytopenia.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: